Nemes Rush Group’s Bristol-Myers Squibb BMY Stock Holding History

Nemes Rush Group’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.59M	Buy	27,548 +1,850	+7%	+$106K	0.13%	93
2026 Q1	$1.56M	Buy	25,698 +130	+0.5%	+$7.58K	0.15%	86
2025 Q4	$1.38M	Sell	25,568 -1,241	-5%	-$59.7K	0.13%	90
2025 Q3	$1.21M	Buy	26,809 +76	+0.3%	+$3.55K	0.12%	89
2025 Q2	$1.24M	Sell	26,733 -294	-1%	-$14.4K	0.13%	91
2025 Q1	$1.65M	Hold	27,027	–	–	0.21%	70
2024 Q4	$1.53M	Buy	27,027 +221	+0.8%	+$12.3K	0.19%	70
2024 Q3	$1.45M	Sell	26,806 -18	-0.1%	-$844	0.21%	73
2024 Q2	$1.11M	Buy	26,824 +18	+0.1%	+$805	0.15%	81
2024 Q1	$1.45M	Buy	26,806 +31	+0.1%	+$1.58K	0.21%	73
2023 Q4	$1.37M	Sell	26,775 -702	-3%	-$36.8K	0.22%	75
2023 Q3	$1.59M	Sell	27,477 -2,491	-8%	-$153K	0.29%	70
2023 Q2	$1.92M	Buy	+29,968	New	+$2.01M	0.34%	61

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nemes Rush Group's BMY Position: Q2 2026 in Review

Nemes Rush Group increased its Bristol-Myers Squibb (BMY) stake by 7.2% in Q2 2026, buying an estimated $106K and bringing the position to 27,548 shares worth $1.59M. The position accounts for 0.13% of the portfolio, ranked #93.

Nemes Rush Group first reported a position in BMY in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.92M in Q2 2023. 2,521 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Nemes Rush Group held 27,548 shares of Bristol-Myers Squibb worth $1.59M as of Q2 2026.
Nemes Rush Group bought 1,850 Bristol-Myers Squibb shares in Q2 2026, an estimated $106K.
Bristol-Myers Squibb made up 0.13% of Nemes Rush Group's portfolio in Q2 2026, its #93 holding.
Nemes Rush Group first reported a position in Bristol-Myers Squibb in Q2 2023 and has held it in 13 quarters since.
Nemes Rush Group's Bristol-Myers Squibb position peaked at $1.92M in Q2 2023.
2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.